Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23113445 | 0.90 | BACE1 (0.42) | CHRNB2CHRNA4KDM1AKDM1BNPC1 | |
| SCHEMBL5321647 | 0.87 | CCNT1 (0.47) | CHRNB2CHRNA4CCNT1CDK9 | |
| SCHEMBL5005427 | 0.84 | HTR1D (0.55) | HTR1DHTR1BMAPTOPRL1 | |
| SCHEMBL30084892 | 0.83 | CHRNB2 (0.41) | CHRNB2CHRNA4KDM1AKDM1BHTR1D | |
| SCHEMBL13014935 | 0.83 | CHRNB2 (0.41) | CHRNB2CHRNA4KDM1AKDM1BHTR1D | |
| Hydrochloric Acid SCHEMBL287323 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4KDM1AKDM1BCRBN | |
| SCHEMBL6937141 | 0.79 | CHRNB2 (0.61) | CHRNB2CHRNA4HTR1DHTR1BCDK9 | |
| SCHEMBL23567637 | 0.79 | CHRNB2 (0.61) | CHRNB2CHRNA4HTR1DHTR1BCDK9 | |
| SCHEMBL3816206 | 0.79 | RBP4 (0.39) | HTR1DHTR1BNPC1OPRL1 | |
| SCHEMBL27701201 | 0.78 | HTR1D (0.35) | CHRNB2CHRNA4HTR1DHTR1BCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | claimed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2025235833-A1 | RXFP1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20230051320-A1 | TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME | ECCOGENE INC. | 2023-02-16 | — | — | US | disclosed |
| CN-110483366-B | Indole compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-09-16 | — | — | CN | disclosed |
| US-20220106288-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-11-20 | — | — | US | disclosed |
| CN-101304747-A | Combinations comprising a VEGF receptor inhibitor and a penetration enhancer | NOVARTIS AG (CH) | 2008-11-12 | — | — | CN | disclosed |
| EP-1984322-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| EP-1945217-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | Novartis AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007090748-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| CN-101018784-A | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2007-08-15 | — | — | CN | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1794149-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | CHRNB2 1538/4885CHRNA4 1627/4885KDM1A 1734/4885 |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | CHRNB2 4439/4885CHRNA4 4340/4885KDM1A 3281/4885 |
| US-20230051320-A1 | TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME | GLP1R, SLC5A1, GIPR | CHRNB2 2070/4885CHRNA4 2028/4885KDM1A 3054/4885 |
| US-20220106288-A1 | NOVEL SULFONEUREA COMPOUNDS | NLRP3, NLRP1, PYCARD | CHRNB2 4698/4885CHRNA4 4591/4885KDM1A 707/4885 |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | CHRNB2 1538/4885CHRNA4 1627/4885KDM1A 1734/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CHRNB2 4775/4885CHRNA4 4834/4885KDM1A 1085/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | CHRNB2 878/4885CHRNA4 777/4885KDM1A 1487/4885 |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | MAP3K20, MAP3K1, MAP3K19 | CHRNB2 4755/4885CHRNA4 4828/4885KDM1A 1252/4885 |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | CHRNB2 2423/4885CHRNA4 2752/4885KDM1A 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.